Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

14

Revenue 2017

Opdivo

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Opdivo was produced by Gilead Sciences.

J&J taps TARIS Biomedical for novel bladder cancer technology

J&J taps TARIS Biomedical for novel bladder cancer technology Most other checkpoint inhibitors also have at least one of those indications on the label, including Roche’s Tecentriq (atezolizumab) and Bristol-Myers Squibb’s Opdivo (nivolumab).

Seattle, Astellas bag speedy FDA okay for bladder cancer drug

Seattle, Astellas bag speedy FDA okay for bladder cancer drug the label, including Roche’s Tecentriq (atezolizumab) and Bristol-Myers Squibb’s Opdivo (nivolumab).

FDA panel clears Keytruda for hard-to-treat bladder cancer

FDA panel clears Keytruda for hard-to-treat bladder cancer Tecentriq (atezolizumab) and Bristol-Myers Squibb’s Opdivo (nivolumab).

AstraZeneca eyes early 2020 FDA verdict on Imfinzi in SCLC

AstraZeneca eyes early 2020 FDA verdict on Imfinzi in SCLC Meantime, Bristol-Myers Squibb also has a phase 2 trial in this setting with its PD-1 inhibitor Opdivo (nivolumab) – also approved for third-line use in SCLC. ... BMS tested Opdivo with its already-approved TLA4 inhibitor Yervoy (ipilimumab) as a

China updates drug reimbursement list, agrees price cuts

China updates drug reimbursement list, agrees price cuts It is the first and only PD-1 inhibitor to be included on the NRDL – Merck’s Keytruda (pembrolizumab) and BMS’ Opdivo (nivolumab) are not present on the updated list. ... However, BMS’ Opdivo claimed the first PD-1 approval in China, when it was

[ Previous 5 results ] 2 3 4 5 6 7 8 9 10 11 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Envision Pharma Group

We are a global leader in the medical affairs space. Our purpose-built software and scientific solutions make us a unique...

Latest intelligence

A snapshot of… Exscientia
...
Patients are ready for virtual clinical trials, are you?
Traditional clinical trial designs simply can’t withstand the impact of COVID-19. While before the pandemic, some in clinical research were beginning to adopt virtual components, the move towards designing hybrid...
Keep your audiences close
How getting up close and personal with target audiences can fuel creativity...

Infographics